Short Wave Pharma
Psilocybin-based Products for Treatment of Mental Health Disorders
Company Overview
Snapshot
Founded in January 2021 by Rivki Stern Youdkevich, Stephen Murphy, and Nadya Lisovoder, Short Wave Pharma operates with 1–10 employees. The company is currently engaged in preclinical studies for its psilocybin-based product targeting anorexia nervosa, signaling its focus on addressing mental health disorders through novel biopharmaceutical approaches.
Business overview
Short Wave Pharma is a biopharmaceutical company specializing in the development of novel formulations of psilocybin and other active pharmaceutical ingredients (APIs). The company focuses on creating customized delivery methods for patients suffering from mental health disorders, neurodegenerative diseases, and chronic pain. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Short Wave Pharma's core technology involves biologicals, targeting the pharmaceutical segment of the healthcare and life sciences market.
Strategic signal
In August 2022, Short Wave Pharma announced a partnership for a clinical trial focused on eating disorders with Sheba Fund. This collaboration highlights the company's strategic validation in the biopharmaceutical space and its commitment to advancing psilocybin-based therapies for mental health conditions, indicating a proactive approach to clinical development and market entry.
Log in to access full profile ›Company Intelligence Q&A
- What is Short Wave Pharma's primary focus?
- Short Wave Pharma is primarily focused on developing novel formulations of psilocybin and other APIs, along with customized delivery methods, for patients with mental health disorders, neurodegenerative diseases, and chronic pain.
- When was Short Wave Pharma founded?
- Short Wave Pharma was founded in January 2021.
- Which medical conditions does Short Wave Pharma aim to address?
- Short Wave Pharma aims to address mental health disorders, neurodegenerative diseases, chronic pain, and other medical conditions where psilocybin has shown positive effects.
- What is Short Wave Pharma's current product development stage?
- Short Wave Pharma has begun preclinical studies related to its product for anorexia nervosa.
- What was a significant partnership for Short Wave Pharma?
- In August 2022, Short Wave Pharma partnered with Sheba Fund for a clinical trial focused on eating disorders.